For Healthcare Professionals

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)


About the study

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Written informed consent
  2. Participants ≥18 years of age or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.
  3. Eastern Cooperative Oncology Group performance status of 0, 1, or 2

Cohort 1 relapsed/refractory peripheral T-cell lymphoma (PTCL):

Diagnosis should be confirmed by the local pathologist; local histological diagnosis will be used for eligibility determination. Participants with the following subtypes of PTCL are eligible according to 2016 WHO classification prior to the initiation of study drug. Any T-cell lymphoid malignancies not listed are excluded. Eligible subtypes include:

  1. Enteropathy-associated T-cell lymphoma
  2. Monomorphic epitheliotropic intestinal T-cell lymphoma
  3. Hepatosplenic T-cell lymphoma
  4. Primary cutaneous γδ T-cell lymphoma
  5. Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  6. PTCL, not otherwise specified
  7. Angioimmunoblastic T-cell lymphoma
  8. Follicular T-cell lymphoma
  9. Nodal PTCL with T-follicular helper (TFH) phenotype
  10. Anaplastic large cell lymphoma, ALK positive
  11. Anaplastic large cell lymphoma, ALK negative
  12. Cohort 2 relapsed/refractory adult T-cell leukemia/lymphoma (ATL) acute, lymphoma, or unfavorable chronic type. Relapsed/refractory ATL should be confirmed by the local pathologist; local diagnosis will be used for eligibility determination. The positivity of anti-human T-cell leukemia virus type 1 (HTLV-1) antibody will be locally determined for eligibility.
  13. Must have at least one lesion which is measurable in 2 perpendicular dimensions on computed tomography (or magnetic resonance imaging) based on local radiological read

Documented refractory, relapsed, or progressive disease after at least 1 prior line of systemic therapy.

Refractory is defined as:

  1. Failure to achieve CR (or CRu for ATL) after first-line therapy
  2. Failure to reach at least PR after second-line therapy or beyond

Must have at least 1 prior line of systemic therapy for PTCL or ATL.

  1. Participants must be considered hematopoietic cell transplantation (HCT) ineligible during screening due to disease status (active disease), comorbidities, or other factors; the reason for HCT ineligibility must be clearly documented.
  2. In the PTCL cohort, participants with anaplastic large cell lymphoma (ALCL) must have prior brentuximab vedotin treatment.


Exclusion Criteria:

Participants meeting any exclusion criteria for this study will be excluded from this study. Below is a list of the key exclusion criteria:

  1. Diagnosis of mycosis fungoides, Sézary syndrome and primary cutaneous ALCL, and systemic dissemination of primary cutaneous ALCL
  2. Diagnosis of precursor T-cell leukemia and lymphoma (T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma), T-cell prolymphocytic leukemia, or T-cell large granular lymphocytic leukemia
  3. Prior malignancy active within the previous 2 years except for locally curable cancer that is currently considered as cured, such as cutaneous basal or squamous cell carcinoma, superficial bladder cancer, or cervical carcinoma in situ, or an incidental histological finding of prostate cancer.
  4. Presence of active central nervous system involvement of lymphoma
  5. History of autologous HCT within 60 days prior to the first dose of study drug
  6. History of allogeneic HCT within 90 days prior to the first dose of study drug
  7. Clinically significant graft-versus-host disease (GVHD) or GVHD requiring systemic immunosuppressive prophylaxis or treatment

Inadequate washout period from prior lymphoma-directed therapy before enrollment, defined as follows:

  1. Prior systemic therapy (eg, chemotherapy, immunomodulatory therapy, or monoclonal antibody therapy) within 3 weeks prior or 5 half-lives of the drug, whichever is longer, to the first dose of study drug
  2. Had curative radiation therapy or major surgery within 4 weeks or palliative radiation therapy within 2 weeks prior to the first dose of study drug

Uncontrolled or significant cardiovascular disease, including:

  1. Evidence of prolongation of QT/QTc interval (eg, repeated episodes of QT corrected for heart rate using Fridericia's method >450 ms) (average of triplicate determinations)
  2. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome
  3. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes
  4. Uncontrolled arrhythmia (subjects with asymptomatic, controllable atrial fibrillation may be enrolled) or asymptomatic persistent ventricular tachycardia
  5. Participant has clinically relevant bradycardia of <50 bpm, unless the participant has a pacemaker
  6. History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers within 6 months prior to Screening
  7. Myocardial infarction within 6 months prior to Screening
  8. Angioplasty or stent craft implantation within 6 months prior to Screening
  9. Uncontrolled angina pectoris within 6 months prior to Screening
  10. New York Heart Association Class 3 or 4 congestive heart failure
  11. Coronary/peripheral artery bypass graft within 6 months prior to Screening
  12. Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg)
  13. Complete left bundle branch block
  14. History of treatment with other EZH inhibitors
  15. Current use of moderate or strong cytochrome P450 (CYP)3A inducers
  16. Systemic treatment with corticosteroids (>10 mg daily prednisone equivalents). Note: Short-course systemic corticosteroids (eg, prevention/treatment for transfusion reaction) or use for a non-cancer indication (eg, adrenal replacement) is permissible.
  17. Known or suspected hypersensitivity to valemetostat tosylate or any of the excipients

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Relapsed/Refractory Peripheral T-Cell Lymphoma,Adult T Cell Leukemia/Lymphoma

Age (in years)



Phase 2

Participants needed


Est. Completion Date

Sep 8, 2025

Treatment type



Daiichi Sankyo, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.